REFERENCES
- Jemal A, Clegg L X, Ward S, et al. Annual report to the nation on the status of cancer, 1975–2001, with a special feature regarding survival. Cancer 2004; 101: 3–27, [INFOTRIEVE]
- Pollack I F, Polinko P, Albright A L. Mutism and pseudobulbar symptoms after resection of posterior fossa tumors in children: incidence and pathophysiology. Neurosurgery 1995; 37: 885–893, [INFOTRIEVE]
- Thomas P RM, Deutsch M, Keppner J L, et al. Low stage medulloblastoma: final analysis of trial comparing standard-dose with reduced-dose neuraxis irradiation. J Clin Oncol 2000; 18: 3004–3011, [INFOTRIEVE]
- Packer R J, Gajjar A, Vezina G, et al. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly-diagnosed average-risk medulloblastoma. J Clin Oncol 2006; 24: 4202–4206, [INFOTRIEVE], [CROSSREF]
- Gilbertson R J. Medulloblastoma: signaling a change in treatment. Lancet Oncol 1998; 5: 209–218, [CROSSREF]
- Duffner P K, Horowitz M E, Krischer J P, et al. Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors. N Engl J Med 1993; 328: 1725–1731, [INFOTRIEVE], [CROSSREF]
- Rutkowski S, Bode U, Deinlein F, et al. Treatment of Early childhood medulloblastoma by postoperative chemotherapy alone. N Engl J Med 2005; 352: 978–986, [INFOTRIEVE], [CROSSREF]
- Mason W P, Grovas A, Halpern S, et al. Intensive chemotherapy and bone marrow rescue for young children with newly diagnosed malignant brain tumors. J Clin Oncol 1998; 16: 210–221, [INFOTRIEVE]
- Sands S, van Gorp W, Finlay J L. Pilot neuropsychological findings from a treatment regimen consisting of intensive chemotherapy and bone marrow rescue for young children with newly diagnosed malignant brain tumors. Child's Nerv Syst 1998; 14: 587–589, [CROSSREF]
- Chi S N, Gardner S, Levy A S, et al. Newly diagnosed high-risk malignant brain tumors with leptomeningeal dissemination in young children: response to “Head Start” induction chemotherapy intensified with high-dose methotrexate. J Clin Oncol 2004; 22: 4881–4887, [INFOTRIEVE], [CROSSREF]
- Gilbertson R J, Gajjar A. Molecular biology of medulloblastomas: will it ever make a difference to clinical management?. J Neuro-oncol 2005; 75: 273–278, [CROSSREF]
- Warren K E. Molecularly targeted therapy for pediatric brain tumors. J Neuro-oncol 2005; 75: 335–343, [CROSSREF]
- Thompson M C, Fuller C, Hogg T L, et al. Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. J Clin Oncol 2006; 24: 1924–1931, [INFOTRIEVE], [CROSSREF]
- Kieran M W. Anti-angiogenesis therapy in pediatric neuro-oncology. J Neuro-oncol 2005; 75: 327–334, [CROSSREF]
- Bocci G, Francia G, Man S, Lawler J, Kerbel R S. Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc Natl Acad Sci U S A 2003; 100: 12917–2922, [INFOTRIEVE], [CROSSREF]